ClinicalTrials.gg
TerminatedNCT06799533Updated Mar 18, 2026

A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors

A Phase 1 interventional study of PF-08046031 in Malignant Melanoma, Melanoma and Metastatic Melanoma, sponsored by Pfizer. Terminated at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies in Melanoma by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Melanoma · Pfizer.

Enrollment
41st of 48
11 · median 77
Started
2025
with 2 others
Phase 1
27 of 52
1 open now
Registered
49th of 52
by date

Among the 52 studies in Melanoma by Pfizer, this one is the 41st largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2025, is one of 27 in phase 1, and was the 49th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 52 studies in Melanoma by Pfizer is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Melanoma by Pfizer, or all of them as a file.
02

Study summary

This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. The study will have 3 parts. Part A and B of the study will find out how much PF-08046031 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046031 is safe and if it works to treat solid tumor cancers.

03

Conditions studied

  • Malignant Melanoma
  • Melanoma
  • Metastatic Melanoma
  • Solid Tumors

Browse trials for

Keywords

  • Solid tumors
  • Other Solid tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants in Part 1 (dose escalation) must have - or cytologically-confirmed or unresectable cutaneous melanoma. They must have progressive disease following at least 1 prior anti programmed death-1 (PD 1)/programmed death-ligand 1 (PD L1) immunotherapy containing regimen (either as monotherapy, or in combination with other or other therapies) and should have no appropriate standard therapy available at the time of enrollment in the judgment of the investigator.
  • Participants in Part 2 (dose optimization) must have histologically- or cytologically-confirmed metastatic or unresectable cutaneous melanoma. They must have progressive disease following at least 1 prior anti PD 1/PD L1 immunotherapy containing regimen (either as monotherapy, or in combination with other checkpoint inhibitors or other therapies) but not more than 2 total and should have no appropriate standard therapy available at the time of enrollment in the judgment of the investigator.
  • For Part 3 (dose expansion): Participants must have histologically- or cytologically confirmed metastatic or unresectable solid from 1 of the following tumor types: cutaneous melanoma, NSCLC, HNSCC, esophageal cancer.

(ECOG) Performance Status score of 0 or 1 per v1.1 at baseline

  • Participants who have refused available standard of care therapies are not eligible.

Exclusion criteria

Exclusion Criteria:

  • Active cerebral/meningeal disease related to the underlying . Previous exposure to CD228-targeted therapy, vedotin or an MMAE-containing agent, or any taxane containing regimen for advanced disease.

Melanoma subtypes including uveal, and mucosal are excluded. Chemotherapy, definitive radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 4 weeks prior to first dose of study intervention, or within 2 weeks prior to first dose of study intervention if the underlying disease has progressed on treatment

  • Grade 3 or higher pulmonary disease unrelated to underlying malignancy. Previous history of non-infectious interstitial lung disease (ILD) or pneumonitis that required , current ILD or pneumonitis, or suspected ILD or pneumonitis that cannot be ruled out by imaging at screening.

Other protocol specific criteria might apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    PF-08046031 monotherapy

    PF-08046031

    Drug: PF-08046031

Interventions

  • DrugPF-08046031

    Given into the vein (IV; intravenous)

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Time frame: through 30 days after the last study treatment; approximately 6 months

  2. Number of participants with laboratory abnormalities

    Time frame: through 30days after the last study treatment; approximately 6 months

  3. Number of participants with dose limiting toxicities

    Time frame: up to 28 days

Secondary outcomes

  1. number of participants with antidrug antibodies

    To be summarized using descriptive statistics

    Time frame: through 30 days after the last study treatment; approximately 6 months

  2. Pharmacokinetic (PK) parameter - Area under the curve (AUC)

    To be summarized using descriptive statistics

    Time frame: Through 30 days after the last study treatment; approximately 6 months

  3. PK parameter - Maximum Concentration (Cmax)

    To be summarized using descriptive statistics

    Time frame: Through 30 days after the last study treatment; approximately 6 months

  4. PK parameter - Time to maximum concentration (Tmax)

    To be summarized using descriptive statistics

    Time frame: Through 30 days after the last study treatment; approximately 6 months

  5. PK parameter - Apparent terminal half-life (t1/2)

    To be summarized using descriptive statistics

    Time frame: Through 30 days after the last study treatment; approximately 6 months

  6. PK parameter - Trough concentration (Ctrough)

    To be summarized using descriptive statistics

    Time frame: Through 30 days after the last study treatment; approximately 6 months

  7. Objective response rate (ORR)

    The proportion of participants with a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by the investigato

    Time frame: Up to approximately 1 year

  8. Duration of response (DOR)

    The time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of progressive disease (PD) (based on radiographic assessments per RECIST v1.1) or death due to any cause

    Time frame: Up to approximately 1 year

  9. Progression-free survival (PFS)

    The time from the start of study treatment to the first documentation of PD (per RECIST v1.1 as assessed by the investigator) or death due to any cause

    Time frame: Up to approximately 1 year

  10. Overall survival (OS)

    The time from the start of study treatment to death due to any cause

    Time frame: Approximately 2 years

07

Study locations

11 sites
  • The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate
    Los Angeles, California 90025, United States
  • The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate
    Los Angeles, California 90025, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94143, United States
  • UCSF Medical Center, Investigational Pharmacy
    San Francisco, California 94158, United States
  • The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only)
    Santa Monica, California 90404, United States
  • Presbyterian/ St. Lukes Medical Center
    Denver, Colorado 80218, United States
  • Sarah Cannon Research Institute at HealthONE - SCRI - PPDS
    Denver, Colorado 80218, United States
  • Gustave Roussy
    Villejuif, Val-de-marne 94800, France
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [barcelona] 08035, Spain
  • Karolinska Universitetssjukhuset Solna
    Solna, Stockholms LÄN [se-01] 171 64, Sweden
  • The Royal Marsden NHS Foundation Trust
    Sutton, SM2 5PT, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Feb 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 29, 2025
StartActual
May 1, 2025
Primary completionActual
Feb 23, 2026
CompletionActual
Feb 23, 2026
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06799533
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
May 1, 2025
Primary completion
Feb 23, 2026
Completion
Feb 23, 2026
Last update
Mar 18, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion